Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov 5;15(11):2591.
doi: 10.3390/pharmaceutics15112591.

Treatment of Dry Eye Disease (DED) in Asia: Strategies for Short Tear Film Breakup Time-Type DED

Affiliations
Review

Treatment of Dry Eye Disease (DED) in Asia: Strategies for Short Tear Film Breakup Time-Type DED

Atsushi Kawahara. Pharmaceutics. .

Abstract

Dry eye disease (DED) is a multifactorial disorder in which tear fluid homeostasis is lost, resulting in increased tear film osmolarity and ocular surface irritation. In Asia, the short tear film breakup time-type DED, which has become a global problem in recent years, is common. While the mainstay of DED treatment in the West is the suppression of inflammation, the first goal of treatment is the stabilization of the tear film in Asia. To date, artificial tears and steroid eye drops have been the main treatment for DED. However, artificial tears require frequent administration of eye drops and thus pose adherence problems, while steroids have problems with side-effects (cataracts, increased intraocular pressure). This review evaluates the new generation therapies in Asia based on what is known about them and demonstrates that they are more effective for DED than traditional therapies such as artificial tears and steroids. Based on considerations, it is proposed that the optimal treatment for the short tear film breakup time-type DED is the initial application of mucin-secretion-enhancing eye drops (long-acting diquafosol) and oral supplements; and if additional treatment is needed, cyclosporine eye drops and the adjunctive therapies presented in this review are added.

Keywords: contact lens; cyclosporine; diquafosol; dry eye; dry eye disease (DED); dry eye syndrome; meibomian gland dysfunction; serum; supplement; tear film.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Figures

Figure 1
Figure 1
The structure of tear film.

Similar articles

Cited by

References

    1. Tangmonkongvoragul C., Chokesuwattanaskul S., Khankaeo C., Punyasevee R., Nakkara L., Moolsan S., Unruan O. Prevalence of symptomatic dry eye disease with associated risk factors among medical students at Chiang Mai University due to increased screen time and stress during COVID-19 pandemic. PLoS ONE. 2022;17:e0265733. doi: 10.1371/journal.pone.0265733. - DOI - PMC - PubMed
    1. The definition and classification of dry eye disease: Report of the Definition and Classification Subcommittee of the International Dry Eye Workshop. Ocul. Surf. 2007;5:75–92. doi: 10.1016/S1542-0124(12)70081-2. - DOI - PubMed
    1. Şimşek C., Doğru M., Kojima T., Tsubota K. Current Management and Treatment of Dry Eye Disease. Turk. J. Ophthalmol. 2018;48:309–313. doi: 10.4274/tjo.69320. - DOI - PMC - PubMed
    1. Stapleton F., Alves M., Bunya V.Y., Jalbert I., Lekhanont K., Malet F., Na K.S., Schaumberg D., Uchino M., Vehof J., et al. TFOS DEWS II Epidemiology Report. Ocul. Surf. 2017;15:334–365. doi: 10.1016/j.jtos.2017.05.003. - DOI - PubMed
    1. Paulsen A.J., Cruickshanks K.J., Fischer M.E., Huang G.H., Klein B.E., Klein R., Dalton D.S. Dry eye in the beaver dam offspring study: Prevalence, risk factors, and health-related quality of life. Am. J. Ophthalmol. 2014;157:799–806. doi: 10.1016/j.ajo.2013.12.023. - DOI - PMC - PubMed

LinkOut - more resources